mid-day summari compil research report summari comment publish roth capit pleas click headlin
comment access copi full research report includ applic disclosur
pleas contact salesperson
initi buy mohawk significantli disrupt sever consum product categori
use proprietari ai-driven technolog platform revenu doubl everi year sinc found
see signific growth ahead share trade discount consum disruptor
mohawk small high-margin saa busi could ultim drive higher valuat
target ipo price reflect absenc close previously-disclos
join three-part nash seri larg nash opportun
dial nash expert call seri three medic expert provid valuabl insight
size nash market real-world use non-invas diagnost techniqu
present prevail nash sentiment low given investor concern true size nash
opportun build awar cover everi inch nash market start current
imag blood test liver biopsi implic novel imag techniqu treatment
decis process expert highlight expect futur nash treatment
advanc would meaning patient physician treatment paradigm
could shift follow introduct new therapi
one-two punch rahimi ph
morn got second half start initi studi core
inhibitor hbv first part studi healthi subject top-line readout
safeti pk data move nuc-suppress patient readout fxr
agonist nash alreadi slate see key catalyst period move
updat estim use actual commod price actual crude
oil versu estim henri hub natur ga
versu estim due slightli lower actual oil price estim
decreas slightli eps/ebitda million million
import disclosur regul ac certif locat end report
updat estim use actual commod price minor adjust actual crude oil
versu estim henri hub natur ga versu estim
new estim eps/ebitda million essenti line previou million
lone announc estim product rate boe per day repres signific out-performance
previous issu guidanc boe per day estim boe per day addit top guidanc boe
per day repres sequenti increas total boe product actual
believ simo repres differenti invest opportun flash embed storag drive control typic quarterli
updat simo announc preliminari revenu low-end previou revenu guidanc gross margin higher believ
near-term weak embed current level still later nand demand recoveri maintain buy rate
page
